TRACON Pharmaceuticals gets FDA clearance for ENVASARC pivotal trial
TRACON Pharmaceuticals (TCON) announced that the FDA has given its nod for a pivotal trial. The company had submitted the protocol as a part of its Investigational New Drug application with the FDA on July 15, 2020. The application had eluded to the open envafolimab IND maintained by TRACON’s corporate partners 3D Medicines and Alphamab Oncology. The company looks to start enrollment for the trial in the fourth quarter of this year.
ENVASARC trial will take place at 25 cancer centers across the United